These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

481 related articles for article (PubMed ID: 29953326)

  • 1. Immunotherapy of Guillain-Barré syndrome.
    Liu S; Dong C; Ubogu EE
    Hum Vaccin Immunother; 2018; 14(11):2568-2579. PubMed ID: 29953326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
    Shahrizaila N; Yuki N
    Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Progress in Guillain-Barré syndrome immunotherapy-A narrative review of new strategies in recent years.
    Yao J; Zhou R; Liu Y; Lu Z
    Hum Vaccin Immunother; 2023 Aug; 19(2):2215153. PubMed ID: 37278272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic strategies in the Guillain-Barré syndrome.
    Kieseier BC; Hartung HP
    Semin Neurol; 2003 Jun; 23(2):159-68. PubMed ID: 12894381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. IVIG treatment and prognosis in Guillain-Barré syndrome.
    van Doorn PA; Kuitwaard K; Walgaard C; van Koningsveld R; Ruts L; Jacobs BC
    J Clin Immunol; 2010 May; 30 Suppl 1(Suppl 1):S74-8. PubMed ID: 20396937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunotherapy of Guillain-Barré syndrome.
    Restrepo-Jiménez P; Rodríguez Y; González P; Chang C; Gershwin ME; Anaya JM
    Expert Opin Biol Ther; 2018 Jun; 18(6):619-631. PubMed ID: 29681203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Guillain-Barré syndrome.
    Fujimura H
    Handb Clin Neurol; 2013; 115():383-402. PubMed ID: 23931791
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome.
    van Doorn PA; Ruts L; Jacobs BC
    Lancet Neurol; 2008 Oct; 7(10):939-50. PubMed ID: 18848313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging treatment landscape for Guillain-Barré Syndrome (GBS): what's new?
    Sprenger-Svačina A; Svačina MKR; Gao T; Zhang G; Sheikh KA
    Expert Opin Investig Drugs; 2024 Sep; 33(9):881-886. PubMed ID: 38980318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Guillain-Barré syndrome: a comprehensive review.
    Bellanti R; Rinaldi S
    Eur J Neurol; 2024 Aug; 31(8):e16365. PubMed ID: 38813755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA; Swan AV; van Doorn PA
    Cochrane Database Syst Rev; 2012 Jul; (7):CD002063. PubMed ID: 22786476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guillain-Barré syndrome following chickenpox: a case series.
    Tatarelli P; Garnero M; Del Bono V; Camera M; Schenone A; Grandis M; Benedetti L; Viscoli C
    Int J Neurosci; 2016; 126(5):478-9. PubMed ID: 26000930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guillain-Barré syndrome: epidemiology, pathophysiology and management.
    Kuwabara S
    Drugs; 2004; 64(6):597-610. PubMed ID: 15018590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Guillain-Barré syndrome in the US hospitals.
    Alshekhlee A; Hussain Z; Sultan B; Katirji B
    J Clin Neuromuscul Dis; 2008 Sep; 10(1):4-10. PubMed ID: 18772694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology.
    Hughes RA; Wijdicks EF; Barohn R; Benson E; Cornblath DR; Hahn AF; Meythaler JM; Miller RG; Sladky JT; Stevens JC;
    Neurology; 2003 Sep; 61(6):736-40. PubMed ID: 14504313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Guillain-Barré syndrome and variants.
    Dimachkie MM; Barohn RJ
    Neurol Clin; 2013 May; 31(2):491-510. PubMed ID: 23642721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Guillain-Barré syndrome].
    Kaida K
    Brain Nerve; 2024 May; 76(5):499-507. PubMed ID: 38741488
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Oculopharyngeal Subtype of Guillain-Barré Syndrome Sparing the Trochlear and Abducens Nerves.
    Arakawa M; Yamazaki M; Toda Y; Ozawa A; Kimura K
    Intern Med; 2020 May; 59(9):1215-1217. PubMed ID: 32023583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances of therapeutic apheresis in Guillain-Barré syndrome.
    Haupt WF
    Ther Apher; 2000 Aug; 4(4):271-4. PubMed ID: 10975472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Treatment of Guillain-Barré Syndrome].
    Nomura K
    Brain Nerve; 2015 Nov; 67(11):1397-410. PubMed ID: 26560955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.